The AI-powered platform provides biomarker insights from standard pathology slides without the need for traditional laboratory staining.

ViewsML will present research on its virtual immunohistochemistry (vIHC) platform at the American Association for Cancer Research (AACR) Annual Meeting, which takes place April 17-22, 2026, in San Diego, CA.

The company will highlight how its platform uses artificial intelligence to provide biomarker insights from a single hematoxylin and eosin (H&E) slide, according to a press release. The technology aims to provide clinical data without the time and cost associated with traditional laboratory staining methods.

One poster, presented with Dartmouth-Hitchcock Medical Center, focuses on virtual immunohistochemical biomarker staining within the lung tumor microenvironment. A second poster, produced in collaboration with HistoWiz, validates the vIHC platform for biomarker classification and intensity binning.

A third presentation, led by Debiopharm International, describes the development of a virtual Cyclin E1 biomarker. This project used deep learning to predict Cyclin E1 overexpression in gynecological malignancies using routine H&E slides.

The platform is designed to extract biomarker insights directly from routine pathology images, which may allow clinicians to analyze staining in minutes rather than days, the company says in a release. This approach delivers spatial biomarker insights while preserving tissue samples that might otherwise be used during traditional laboratory workflows.

The company says its technology is “transforming biomarker detection” by moving tissue analysis from a laboratory process into software, according to the release. ViewsML will demonstrate the platform at booth 1557 during the AACR meeting.

Photo caption: virtual immunohistochemistry (vIHC) platform

Photo credit: ViewsML

Related Reading: